NCT01064505已完成1 期
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Quark Pharmaceuticals28 个研究点 分布在 2 个国家目标入组 48 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 28
- 主要终点
- To determine the safety, tolerability and the dose-limiting toxicities (DLTs) of QPI 1007 when administered as a single intravitreal (IVT) injection.
研究概览
简要总结
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
This study will determine whether QPI-1007 is safe when it is injected into the eye. The study will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.
详细描述
Patients will be enrolled according to one of two sets of criteria designated as Stratum I and Stratum II.
- Stratum I will enroll Optic Nerve Atrophy patients who meet necessary criteria. Stratum I will consist of a maximum of 6 cohorts and each cohort will enroll 3 to 6 evaluable patients. Enrollment in Stratum I is now closed.
- Stratum II will enroll patients diagnosed with acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION) within 28 days of symptom onset who meet necessary criteria. Stratum II will consist of a maximum of 3 cohorts and each cohort will enroll up to 10 evaluable patients. Enrollment in Stratum II is still open.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •"Legally blind" in the study eye as the result of an irreversible condition affecting the posterior segment of the eye.
- •Clear ocular media and able to undergo adequate pupil dilation.
- •Visual acuity and visual field in the non-study eye are better than or equal to the study eye
- •At least 21 years old.
- •Key Stratum I (Chronic Optic Nerve Atrophy)
排除标准
- •For the study eye only: history of any IVT injection or vitrectomy, vitreous hemorrhage, retinal detachment, or active inflammatory condition (e.g. conjunctivitis).
- •For either eye: history of uveitis.
- •Enrollment is now closed in Stratum I.
- •Key Stratum II (Acute NAION) Inclusion Criteria:
- •Positive diagnosis of NAION with symptom onset within 28 days prior to planned dosing with QPI-
- •Visual acuity in the study eye is between 20/40 and light perception.
- •Clear ocular media and able to undergo adequate pupil dilation.
- •At least 50 years old.
- •Key Stratum II (Acute NAION) Exclusion Criteria:
- •For the study eye only: Macular disease, retinopathy, or other eye disease limiting visual acuity; prior intraocular surgery (other than Lasik) and cataract surgery within 3 months prior to dosing; glaucoma laser surgery within 1 month prior to dosing; pain on or aggravated by eye movement; history of vitreous hemorrhage; history of retinal detachment; any active inflammatory condition (e.g. conjunctivitis); glaucoma or ocular hypertension; or intraocular pressure > 26 mmHg.
- •For either eye: History of optic neuritis; or history of uveitis.
- •Received any treatment for NAION prior to dosing.
- •Any other abnormality which in the opinion of the investigator is suggestive of a disease other than NAION in the study eye only.
- •Clinical evidence of temporal arteritis.
- •History of collagen vascular disease or other inflammatory disease, or history of multiple sclerosis.
- •Enrollment in Stratum II is still open.
研究组 & 干预措施
QPI-1007
Experimental
干预措施: QPI-1007 at various doses (Drug)
结局指标
主要结局
To determine the safety, tolerability and the dose-limiting toxicities (DLTs) of QPI 1007 when administered as a single intravitreal (IVT) injection.
时间窗: 12 Months Post-injection
To assess the pharmacokinetics (PK) of QPI-1007 when administered as a single IVT injection.
时间窗: 12 Months Post-Injection
次要结局
- To determine the presence of and to describe any anatomical changes in the optic nerve head and retina observed following the administration of a single IVT injection of QPI 1007.(12 Months Post-Injection)
- To assess any changes in visual acuity and visual field observed following the administration of a single IVT injection of QPI-1007.(12 Months Post-Injection)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
1 期
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaAML, AdultCLL, RelapsedCLL, RefractoryAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaCLLNCT04512105University of California, Irvine6
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
终止
1 期
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.CancerNCT01248858GlaxoSmithKline69
已完成
1 期
Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)HealthyNCT03401320Rovi Pharmaceuticals Laboratories53
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsAdvanced MalignanciesNCT04353830Innovent Biologics (Suzhou) Co. Ltd.34